SCHEMBL25411880

SCHEMBL25411880

CCCC[C@H]1CN(S(=O)(=O)c2ccc(C)cc2)c2cccc(C=O)c21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.37
▸ UBE2N P61088 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ KCNN4 O15554 1/20 0.37
▸ KCNA3 P22001 1/20 0.37
▸ ACHE P22303 1/20 0.36
▸ CRHBP P24387 1/20 0.36
▸ CRHR2 Q13324 1/20 0.36
▸ LMNA P02545 3/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ MMP2 P08253 1/20 0.36
▸ HTR6 P50406 2/20 0.35
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ DRD3 P35462 1/20 0.33
▸ CD4 P01730 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25411887 1.00 KDM4E (0.37) KDM4EUBE2NALDH1A1KCNN4KCNA3
SCHEMBL26307937 0.94 KDM4E (0.39) KDM4EUBE2NALDH1A1KCNN4KCNA3
SCHEMBL25411163 0.89 KCNN4 (0.42) KDM4EUBE2NALDH1A1KCNN4KCNA3
SCHEMBL25411156 0.89 KCNN4 (0.42) KDM4EUBE2NALDH1A1KCNN4KCNA3
SCHEMBL25413830 0.85 KDM4E (0.39) KDM4EUBE2NALDH1A1KCNN4KCNA3
SCHEMBL25413834 0.85 KDM4E (0.39) KDM4EUBE2NALDH1A1KCNN4KCNA3
SCHEMBL25412408 0.84 ALDH1A1 (0.40) KDM4EUBE2NALDH1A1KCNN4KCNA3
SCHEMBL25412405 0.84 ALDH1A1 (0.40) KDM4EUBE2NALDH1A1KCNN4KCNA3
SCHEMBL26307939 0.84 ALDH1A1 (0.40) KDM4EUBE2NALDH1A1KCNN4KCNA3
SCHEMBL25411450 0.83 ALDH1A1 (0.40) KDM4EUBE2NALDH1A1KCNN4KCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278959-A1 Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization MISSISSIPPI STATE UNIVERSITY 2023-09-07 — — US disclosed
US-20230278959-A1 Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization MISSISSIPPI STATE UNIVERSITY 2023-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278959-A1 Synthesis of Optically Active Indoline Derivatives Via Ruthenium(II)-Catalyzed Enantioselective C-H Functionalization INMT, IDO2, WEE2 KDM4E 2468/4885UBE2N 1961/4885ALDH1A1 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback